Absci to Participate in Upcoming Investor Conferences
Absci to Participate in Upcoming Investor Conferences
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
2024年8月21日，华盛顿温哥华和纽约（全球货币）Absci Corporation（纳斯达克：ABSI），一家以数据为先导的生成式人工智能药物创造公司，今天宣布该公司将参加以下即将举行的投资者会议。
-
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside chat on Thursday, September 5th at 5:35 p.m. Eastern Time
- 摩根士丹利第22届全球医疗保健大会
9月5日星期四下午5:35（东部时间）炉边聊天
-
Citi 2024 Global TMT Conference
Fireside chat on Friday, September 6th at 8:20 a.m. Eastern Time
- 2024年花旗全球TMT会议
9月6日星期五上午8:20（东部时间）炉边聊天
-
H.C. Wainwright 26th Annual Global Investment Conference
Fireside chat on Tuesday, September 10th at 12:00 p.m. Eastern Time
- 汉肯莱特第26届全球投资大会
9月10日星期二下午12:00（东部时间）炉边聊天
Interested parties may access live and archived webcasts of these events on the company's investor relations website at: investors.absci.com.
有兴趣的人可以在公司投资者关系网站上观看这些事件的直播和存档网络广播。 investors.absci.com.
About Absci
关于Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci是一家将人工智能与可扩展实验室技术相结合的数据导向的生成AI药物研发公司，旨在更快地为患者创建更好的生物制品。我们的综合药物创新平台通过同时优化开发和治疗效益的多个药物特性，释放加速临床时间并增加成功率的潜力。凭借训练数据、人工智能和湿实验验证，我们可以每周筛选数十亿个细胞，从AI设计的抗体到湿实验验证的候选药物只需短短六周。Absci的总部位于华盛顿温哥华市，AI研究实验室位于纽约市，创新中心位于瑞士楚格。 该平台通过同时优化多种对开发和治疗效益都重要的多种药物特征，释放加速进入临床阶段和增加成功概率的潜力。凭借用于训练数据的人工智能，创造人工智能和用于验证的实验室，我们每周可以筛查数十亿个细胞，使我们能够在仅仅六周的时间内从人工智能设计的候选人转变为实验室验证的候选人。Absci的总部位于华盛顿州温哥华，我们的人工智能研究实验室位于纽约市，创新中心位于瑞士楚格。访问 ，以及 Twitter(@Abscibio)@absci，以及 Twitter(@Abscibio)@Abscibio）以及YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投资者联系方式
Alex Khan
财务与投资者关系副总裁
investors@absci.com
Media Contact
press@absci.com
媒体联系人
press@absci.com
